What is the recommended ampicillin‑sulbactam (Unasyn) dosing regimen for an adult with a multidrug‑resistant infection and chronic kidney disease, adjusted for creatinine clearance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ampicillin-Sulbactam (Unasyn) Dosing for Multidrug-Resistant Infections in CKD Patients

For patients with chronic kidney disease and multidrug-resistant infections, ampicillin-sulbactam dosing must be adjusted based on creatinine clearance, with the standard dose of 1.5-3 g every 6-8 hours reduced to every 12 hours for CrCl 15-29 mL/min and every 24 hours for CrCl 5-14 mL/min, not to exceed 4 grams of sulbactam daily. 1

Standard Dosing in Normal Renal Function

  • The recommended adult dose is 1.5 g (1 g ampicillin/0.5 g sulbactam) to 3 g (2 g ampicillin/1 g sulbactam) every 6 hours via slow IV injection over 10-15 minutes or IV infusion over 15-30 minutes 1
  • For severe multidrug-resistant infections, particularly Acinetobacter baumannii, higher doses of 9-12 g/day of sulbactam component (corresponding to 18-24 g/day total ampicillin-sulbactam) in 3 divided doses are recommended 2
  • The total sulbactam dose should not exceed 4 grams per day in standard dosing 1

Renal Dose Adjustments

The FDA-approved dosing adjustments based on creatinine clearance are:

  • CrCl ≥30 mL/min: 1.5-3 g every 6-8 hours 1
  • CrCl 15-29 mL/min: 1.5-3 g every 12 hours 1
  • CrCl 5-14 mL/min: 1.5-3 g every 24 hours 1

Pharmacokinetic Rationale

  • Both ampicillin and sulbactam are eliminated primarily by the kidneys (approximately 71% and 78%, respectively), and their elimination kinetics are similarly affected by renal impairment 3, 4
  • The half-life increases from approximately 1 hour in normal renal function to over 17 hours in end-stage renal disease 3, 5
  • The ratio of ampicillin to sulbactam remains constant regardless of renal function, so the fixed combination can be adjusted proportionally 3, 5

Hemodialysis Patients

For patients on maintenance hemodialysis:

  • Administer 1.5-3 g every 24 hours, with dosing given after hemodialysis on dialysis days 1, 3
  • Hemodialysis removes approximately 35% of ampicillin and 45% of sulbactam during a 4-hour treatment 3
  • The half-life during hemodialysis decreases to approximately 2.2-2.3 hours for both drugs 3

Extended Daily Dialysis Considerations

  • For critically ill patients with acute kidney injury undergoing extended daily dialysis (8-hour sessions), a twice-daily dosing schedule of at least 2 g/1 g ampicillin-sulbactam is required to avoid underdosing 6, 4
  • One dose should be administered after dialysis 4
  • Standard hemodialysis dosing (once daily) results in significant underdosing in extended dialysis due to enhanced clearance 6

Continuous Renal Replacement Therapy (CRRT)

  • For critically ill patients receiving CRRT, standard dosing recommendations for intermittent hemodialysis cannot be directly applied 7
  • Antibiotic pharmacokinetics differ significantly in CRRT compared to normal renal function or intermittent hemodialysis 7
  • Consultation with infectious diseases and nephrology specialists is recommended for optimal dosing in CRRT patients 7

Critical Considerations for Multidrug-Resistant Organisms

For MDR Acinetobacter baumannii infections specifically:

  • Sulbactam has intrinsic activity against Acinetobacter species at MIC ≤4 mg/L 2
  • Higher doses (9-12 g/day of sulbactam component) are recommended for severe infections in patients with normal renal function 2
  • In CKD patients with MDR infections, proportional dose reduction based on creatinine clearance should be applied to these higher doses while maintaining therapeutic levels 2

Important Caveats

  • β-lactamase-producing strains: Ampicillin-sulbactam is effective against β-lactamase-producing enterococci, with 6 weeks of therapy recommended for endocarditis 2
  • Monitoring: Assess clinical response within 48-72 hours and reassess renal function every 2-3 days to adjust dosing as renal function changes during treatment 8
  • Avoid underdosing: In critically ill patients with changing renal function or those on renal replacement therapy, err on the side of adequate dosing rather than excessive dose reduction, as underdosing increases mortality risk with MDR infections 6, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis--a single case.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009

Research

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005

Guideline

Meropenem Dosing for Elderly Patients with Urosepsis and Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the maximum dose of sulbactam (Sulbactam) per day when used in combination with ampicillin (Ampicillin) for a standard adult patient with normal renal function?
Can Unasyn (ampicillin/sulbactam) cause hyponatremia in patients with End-Stage Renal Disease (ESRD)?
What is the dosage adjustment for ampicillin (Ampicillin)/sulbactam in a patient with impaired renal function?
What is the recommended dosing of ampicillin (Ampicillin) for a patient with impaired renal function (IRF) undergoing dialysis?
What is the appropriate renal‑adjusted ampicillin dosing regimen for an adult patient on intermittent hemodialysis (three 3–4‑hour sessions per week) being treated for Enterococcus faecalis infection?
What are the approved indications for nintedanib (Ofev) in fibrotic lung diseases and non‑small cell lung cancer?
What is the recommended immediate management for a patient with septic shock secondary to pneumonia?
What are tirzepatide's effects on adipose tissue loss, its efficacy and safety, recommended dosing schedule, and long‑term adverse effects in adults?
What is the recommended intravenous dosing, infusion rate, monitoring, contraindications, and adverse effects of ferric pyrophosphate liposomal for an adult with iron‑deficiency anemia who has no known hypersensitivity to iron products?
How can anxiety management be augmented in a 79‑year‑old male taking escitalopram 10 mg daily, clonazepam 2 mg daily, and alprazolam 0.25 mg as needed (pro re nata, max 1.5 mg/day)?
How can secondary ST‑T changes be differentiated from the criteria for Wellens syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.